Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Kaufmann, R; Spieth, K; Leiter, U; Mauch, C; von den Driesch, P; Vogt, T; Linse, R; Tilgen, W; Schadendorf, D; Becker, JC; Sebastian, G; Krengel, S; Kretschmer, L; Garbe, C; Dummer, R.
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
J Clin Oncol. 2005; 23(35):9001-9007 Doi: 10.1200/JCO.2005.01.1551 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Becker Jürgen Christian
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: PURPOSE: Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma. As the combination with interferon-alfa (IFN-alpha) appears superior to single-agent DTIC regarding response rates, the purpose of this study was to compare TMZ alone and TMZ plus IFN-alpha in terms of objective response (OR), overall survival, and safety in a prospective, randomized, multicenter trial. PATIENTS AND METHODS: Two hundred ninety-four patients with untreated stage IV metastatic melanoma (American Joint Committee on Cancer staging system) were randomly assigned to receive either oral TMZ alone (200 mg/m2/day; days 1 through 5 every 28 days) or in combination with subcutaneous IFN-alpha (5 MU/m2; days 1, 3, and 5 every week). RESULTS: Two hundred eighty-two patients were eligible for an intent-to-treat analysis, 271 patients were treated per protocol. In the TMZ + IFN-alpha arm, 33 (24.1%) of 137 patients responded to therapy (partial or complete remission) whereas in the monotherapy arm, in 18 (13.4%) of 134 patients, a response was evident. Thus, the response rate was significantly higher in the combination arm (P = .036). Median survival time was 8.4 months for patients treated with TMZ (95% CI, 7.07 to 9.27) and 9.7 months for those treated with the combination (95% CI, 8.26 to 11.18; P = .16). Dose modifications and interval prolongations due to hematologic toxicity were significantly more frequent in the TMZ + IFN-alpha arm (P < .001). CONCLUSION: In metastatic melanoma treatment with TMZ + IFN-alpha leads to a significantly superior OR rate compared to treatment with TMZ alone, which did not translate into prolonged survival in our study population.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chi-Square Distribution -; Dacarbazine - administration and dosage Dacarbazine - analogs and derivatives; Female -; Humans -; Interferon-alpha - administration and dosage; Male -; Melanoma - drug therapy Melanoma - pathology; Middle Aged -; Prognosis -; Prospective Studies -; Statistics, Nonparametric -; Survival Rate -; Treatment Outcome -